Advertisement
UK markets closed
  • NIKKEI 225

    40,580.76
    +506.06 (+1.26%)
     
  • HANG SENG

    17,978.57
    +209.47 (+1.18%)
     
  • CRUDE OIL

    83.88
    +1.07 (+1.29%)
     
  • GOLD FUTURES

    2,369.40
    +36.00 (+1.54%)
     
  • DOW

    39,308.00
    -23.90 (-0.06%)
     
  • Bitcoin GBP

    46,853.00
    -1,758.30 (-3.62%)
     
  • CMC Crypto 200

    1,251.12
    -83.79 (-6.28%)
     
  • NASDAQ Composite

    18,188.30
    +159.54 (+0.88%)
     
  • UK FTSE All Share

    4,463.09
    +33.43 (+0.75%)
     

Top ASX Stocks Estimated as Undervalued for Investment Opportunities in July 2024

As the Australian market navigates through varied sector performances with the ASX200 recently closing down slightly, opportunities for investment can emerge from analyzing undervalued stocks. Given current conditions, such as the recovery in iron ore prices and specific sector movements, identifying stocks that are priced below their intrinsic value could offer potential growth prospects for investors.

Top 10 Undervalued Stocks Based On Cash Flows In Australia

Name

Current Price

Fair Value (Est)

Discount (Est)

MaxiPARTS (ASX:MXI)

A$1.97

A$3.91

49.6%

GTN (ASX:GTN)

A$0.445

A$0.85

47.5%

ReadyTech Holdings (ASX:RDY)

A$3.21

A$6.25

48.6%

hipages Group Holdings (ASX:HPG)

A$1.055

A$2.09

49.5%

IPH (ASX:IPH)

A$6.20

A$11.98

48.3%

Regal Partners (ASX:RPL)

A$3.22

A$6.18

47.9%

Australian Clinical Labs (ASX:ACL)

A$2.51

A$4.74

47%

Strike Energy (ASX:STX)

A$0.235

A$0.44

46.9%

Millennium Services Group (ASX:MIL)

A$1.145

A$2.24

48.9%

SiteMinder (ASX:SDR)

A$5.09

A$10.01

49.2%

Click here to see the full list of 46 stocks from our Undervalued ASX Stocks Based On Cash Flows screener.

ADVERTISEMENT

Let's uncover some gems from our specialized screener

Australian Clinical Labs

Overview: Australian Clinical Labs Limited operates in the pathology services sector within Australia and has a market capitalization of approximately A$503.26 million.

Operations: The company generates its revenue primarily from medical labs and research, totaling approximately A$674.03 million.

Estimated Discount To Fair Value: 47%

Australian Clinical Labs is trading at A$2.51, significantly below the estimated fair value of A$4.74, highlighting its undervaluation based on discounted cash flow analysis. Despite slower revenue growth forecasts at 4.6% annually compared to the market, ACL's earnings are expected to surge by 20.99% per year over the next three years, outpacing the Australian market's forecast of 13%. However, current profit margins have dipped to 2.3%, a decrease from last year's 9%, and financial results have been affected by large one-off items.

ASX:ACL Discounted Cash Flow as at Jul 2024
ASX:ACL Discounted Cash Flow as at Jul 2024

IPD Group

Overview: IPD Group Limited, operating in Australia, specializes in the distribution of electrical equipment and has a market capitalization of approximately A$485.89 million.

Operations: The company generates revenue through its Products Division, which brought in A$215.98 million, and its Services Division, which contributed A$20.79 million.

Estimated Discount To Fair Value: 14.6%

IPD Group is currently priced at A$4.70, under the calculated fair value of A$5.50, suggesting a modest undervaluation based on cash flow analysis. The company's earnings have increased by 22.4% over the past year and are expected to grow by 25.88% annually for the next three years, significantly outstripping the Australian market's growth rate of 13%. However, there has been considerable insider selling recently, and shareholder dilution occurred over the past year, tempering its investment appeal.

ASX:IPG Discounted Cash Flow as at Jul 2024
ASX:IPG Discounted Cash Flow as at Jul 2024

PWR Holdings

Overview: PWR Holdings Limited specializes in designing, prototyping, producing, testing, validating, and selling cooling products and solutions across Australia, the United States, the United Kingdom, Italy, Germany and other international markets with a market capitalization of approximately A$1.10 billion.

Operations: The company's revenue is primarily generated through two segments: PWR C&R, which contributed A$37.35 million, and PWR Performance Products, which added A$104.44 million.

Estimated Discount To Fair Value: 20.3%

PWR Holdings is trading at A$10.94, below the estimated fair value of A$13.73, indicating a 20.3% undervaluation based on discounted cash flow analysis. While its earnings have grown by 12.3% over the past year, they are expected to increase by 15.36% annually, outpacing the Australian market's forecast growth of 13%. However, revenue growth projections are less robust at 12.9% per year compared to more aggressive market averages.

ASX:PWH Discounted Cash Flow as at Jul 2024
ASX:PWH Discounted Cash Flow as at Jul 2024

Turning Ideas Into Actions

Curious About Other Options?

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include ASX:ACL ASX:PWH and

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com